DB
DBV.F DBV Technologies S.A.
- Market cap
- EUR 647M
- P/E
- -
- P/B
- 4.58x
- ROE
- -145.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DBV.F undervalued?
Graham numberThe Graham number of DBV Technologies S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DBV Technologies S.A. fundamental analysis
No fundamental analysis for DBV Technologies S.A. yet.
DBV Technologies S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.…
Full company profileDBV Technologies S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DBV Technologies S.A. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.71M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
| Operating Income | -116M | -145M | -166M | -152M | -135M | -99.5M | -96.6M | -76.4M | -117M | -147M | -218M |
| EBITDA | - | -141M | -163M | -146M | -148M | -86.3M | -83.5M | -67.3M | -109M | -139M | -206M |
| Net Income | -115M | -148M | -166M | -154M | -160M | -97.8M | -96.3M | -72.7M | -114M | -147M | -217M |
| EPS | - | -5.91 | -5.51 | -3.27 | -2.91 | -1.78 | -1.02 | -0.76 | -1.11 | -0.62 | -0.69 |
| Balance Sheet | |||||||||||
| Total Assets | 288M | 178M | 172M | 241M | 272M | 147M | 247M | 183M | 65.7M | 234M | 215M |
| Total Liabilities | 44.7M | 47.9M | 50.5M | 69.9M | 66.8M | 47.4M | 52.0M | 42.8M | 38.3M | 64.9M | 66.8M |
| Shareholders' Equity | 243M | 130M | 121M | 172M | 205M | 99.3M | 195M | 140M | 27.4M | 169M | 149M |
| Cash & Short-term Investments | 256M | 138M | 123M | 172M | 196M | 77.3M | 209M | 141M | 32.5M | 194M | 166M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -59.5M | -114M | -137M | -148M | -166M | -108M | -55.7M | -79.7M | -104M | -121M | -204M |
| Capital Expenditure | 8.21M | 7.25M | 4.71M | 5.57M | 2.79M | 910K | 754K | 677K | 2.34M | 538K | 4.00M |
| Free Cash Flow | - | -122M | -141M | -134M | -168M | -109M | -55.7M | -80.3M | -107M | -122M | -208M |
| Ratios | |||||||||||
| ROE | -47.2% | -113.7% | -136.9% | -89.5% | -77.6% | -98.5% | -49.5% | -51.9% | -415.9% | -87.1% | -145.8% |
| ROA | -39.8% | -83.1% | -96.7% | -63.6% | -58.6% | -66.7% | -39.1% | -39.7% | -173.5% | -62.9% | -100.6% |
| Net Profit Margin | - | - | - | - | - | -1,713.5% | -2,006.3% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
DBV Technologies S.A. dividends
DBV Technologies S.A. has not paid dividends in the last 9 fiscal years.
Who owns DBV Technologies S.A.
- Insiders 0.13%
- Institutions 56.54%
- Public & others 43.33%
- Shares outstanding 314M
- Free float 178M
DBV Technologies S.A. company profile
- Company name
- DBV Technologies S.A.
- Ticker
- DBV.F
- ISIN
- FR0010417345
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 179
- Fiscal year end
- December
- Address
- BAtiment IRO, Châtillon, France, 92320
- Phone
- 33 1 55 42 78 78
- Website
- dbv-technologies.com
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
DBV Technologies S.A. management
5- Mr. Daniel TasséCEO & Director · born 1960
- Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.Chief Financial Officer · born 1969
- Dr. Pharis Mohideen M.D.Chief Medical Officer · born 1965
- Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.Chief Operations Officer
- Mr. Jonathan NeelyVP & Head of Investor Relations